EMA confirms benefits of BI's Pradaxa but wants clearer guidance
The European Medicines Agency has recommended updating the product information for Boehringer…See More
Pharmaceutical Social Network
PharmaBusiness.com
Pharmaceutical Social Network. Business information services for the medical and pharmaceutical industries and professionals.
Latest Activity
Michael Honatan posted a discussionOsiris GvHD therapy is world's first approved stem cell drug
Osiris Therapeutics has been given the green light by regulators in Canada for Prochymal, its…See More
Maria Burneo posted a discussionRoche scraps cholesterol drug dalcetrapib after Phase III fail
Shares in Roche have taken a bashing after the Swiss major has pulled the plug on dalcetrapib, a…See More
Groups
-
Pfizer
22 members
-
Bayer
19 members
-
Novartis
18 members
-
Sanofi Aventis
16 members
-
Eli Lilly
14 members
-
ROCHE
14 members
-
Merck
13 members
-
PARC CIENTÍFIC BARCELONA…
12 members
-
GlaxoSmithKline
12 members
-
Jobs
12 members
Forum
EMA confirms benefits of BI's Pradaxa but wants clearer guidance
Started by Pharmaceutical 18 hours ago. 0 Replies 0 Likes
The European Medicines Agency has recommended updating the product information for Boehringer Ingelheim's new blockbuster bloodthinner Pradaxa concerning the risk of bleeding but has again stressed the benefits of the drug.Noting that "bleeding is a…Continue
Osiris GvHD therapy is world's first approved stem cell drug
Started by Michael Honatan on Monday. 0 Replies 0 Likes
Osiris Therapeutics has been given the green light by regulators in Canada for Prochymal, its treatment for acute graft-versus host disease in children, making it the world’s first approved drug which has a stem cell as its active ingredient.The US…Continue
Roche scraps cholesterol drug dalcetrapib after Phase III fail
Started by Maria Burneo May 8. 0 Replies 0 Likes
Shares in Roche have taken a bashing after the Swiss major has pulled the plug on dalcetrapib, a drug which raises 'good' cholesterol, after suffering a late-stage study failure.On the basis of results from the second interim analysis of the…Continue
Tags: Phase, III, fail, after, dalcetrapib
Abbott acquires kidney drug from Action for $110 million
Started by Michael Honatan May 7. 0 Replies 0 Likes
Abbott Laboratories is shelling out $110 million to buy an investigational kidney drug from Denmark's Action Pharma.The treatment in question, AP214, is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in…Continue
Featured news
D-Day for Lipitor as scramble for US market share begins
Posted by Nicolás Mena on November 30, 2011 at 9:51pm 0 Comments 0 Likes
Lipitor, the world's best-selling drug, goes off-patent in the USA today, and observers are watching keenly to see how damaging the loss will be to Pfizer and how much generics firms will benefit.
Pfizer is fighting hard to keep hold of a…
Continue
Novartis triple-combo blood pressure drug gets European OK
Posted by Elisa Marferson on November 28, 2011 at 11:55pm 0 Comments 0 Likes
Novartis has been given the green light to market its triple combination antihypertensive Rasitrio.
The European Commission has approved Rasitrio as a single pill for the treatment of high blood pressure. It combines the Swiss…
Continue Facebook in firing line over tale of two Mercks
Posted by Michael Honatan on November 24, 2011 at 8:56pm 0 Comments 0 Likes
Germany's Merck KGaA has asked a New York judge to force Facebook to provide information about "an apparent takeover" of its page on the social networking site, which is now occupied by information on rival Merck & Co.
Robert Horowitz…
Continue EU approves Pfizer's Vyndaqel, FDA backs Prevnar 13 expansion
Posted by Nicolás Mena on November 17, 2011 at 9:15pm 0 Comments 0 Likes
The European Commission has approved Pfizer's Vyndaqel for the treatment of a rare genetic disease.
Vyndaqel (tafamidis) has been given the green light for transthyretin familial amyloid polyneuropathy (TTR-FAP), a progressive and fatal…
Continue US CBO doubles estimated savings from pay-for-delay ban
Posted by Nicolás Mena on November 14, 2011 at 8:29pm 0 Comments 0 Likes
The US Congressional Budget Office (CBO) now estimates that banning "pay-for-delay" deals between brand-name and generic drugmakers would reduce the federal deficit by $4.8 billion over 10 years; last year it said the measure would cut…
Continue AstraZeneca/Targacept antidepressant fails Phase III study
Posted by Nicolás Mena on November 8, 2011 at 8:18pm 0 Comments 0 Likes
AstraZeneca and partner Targacept have announced disappointing top-line results from the first of four late-stage studies on their new antidepressant.
Specifically, the Renaissance 3 Phase III study investigated TC-5214 as an adjunct…
Continue
Videos
Badge
© 2012 Created by ROSMA.
